Comprehensive characterization of a novel, oncogenic and targetable SEPTIN6::ABL2 fusion in T-ALL. Lahera A, Vela-Martin L, Lopez-Nieva P, Salgado RN, et al. Br J Haematol 2023;202:693-698.

Read + Share

Amedeo Smart

Independent Medical Education

Read + Share

Lahera A, Vela-Martin L, Lopez-Nieva P, Salgado RN, et al. Comprehensive characterization of a novel, oncogenic and targetable SEPTIN6::ABL2 fusion in T-ALL. Br J Haematol 2023;202:693-698.
PMID: 37264982